Search
Dr. Luciano Potena: Advancing Heart Transplantation with Empathy
Dr. Potena’s path into advanced heart failure and transplantation began early, through thesis work focused on rejection monitoring, which helped shape a sustained clinical and research interest in transplant medicine
Meet Dr. Luciano Potena
Dr. Luciano Potena’s path into transplant cardiology began in medical school, when he chose a project on heart transplantation for his thesis work. Early on, he was introduced to a then-promising effort to diagnose myocardial rejection non-invasively using electrocardiogram (ECG) analysis. This experience helped launch his long-term focus on treating patients with advanced heart failure and transplantation.
What drew him in (and what has kept him in the field) was his interest in caring for patients with severe, life-threatening diseases. Transplantation can significantly impact a patient’s clinical course, but it also demands long-term, multidisciplinary, medically complex care that extends far beyond a single procedure.
Career Overview: Clinical Focus, Philosophy and Leadership
Dr. Potena’s path into advanced heart failure and transplantation began early, through thesis work focused on rejection monitoring, which helped shape a sustained clinical and research interest in transplant medicine. He is drawn to transplant cardiology for its breadth, grounded in internal medicine and immunology and for the opportunity to care for the whole person rather than just treat a single disease.
Key mentors and formative experiences played a defining role in his approach. Carlo Magelli helped him develop the foundations of how to communicate with and care for patients, emphasizing the human component of advanced heart failure and transplant care. During his time at Stanford, Hannah Valantine mentored him on work related to cytomegalovirus (CMV) infection and coronary artery disease in transplant patients, while also highlighting the importance of clinical collaboration in improving outcomes.
Today, Dr. Potena serves as Director of the Heart Failure and Transplantation Unit and Cardiovascular Internal Medicine at the IRCCS Bologna Academic Hospital. In addition to clinical leadership, much of his role involves team management, research planning and oversight, as well as close coordination on complex clinical cases, where he brings together multidisciplinary experience to support challenging patient needs.
Key Achievements: Clinical Contributions and Longitudinal Care Focus
Over the course of his career, Dr. Potena has contributed to clinical experience in the management of antibodies and antibody-mediated rejection (AMR) in clinical practice, bringing clinicians together into a focused community to address these complex, high-stakes challenges. He also contributed to early research related to the Molecular Microscope Diagnostic System (MMDx), a diagnostic approach that has been explored in transplant medicine.
Today, Dr. Potena continues to contribute to a clinical environment grounded in complex, team-based, longitudinal care, where the transplant event is viewed not as the finish line, but as the beginning of long-term patient management. From this patient-centered perspective, he has emphasized both the emotional and clinical significance of caring for transplant patients across a long arc, from critical illness, through years of stability and health and at times through end-of-life, supporting patients and families at every stage.
Two Priorities: AMR Treatment and Tailored Immunosuppression
Dr. Potena highlighted persistent unmet needs in transplantation, particularly around AMR treatment and more precise immunosuppression management. In his view, these challenges are tightly connected. First, he noted the need for a proven, effective therapy for AMR, mentioning that many current approaches involve combinations of therapies informed from retrospective, single-center experience rather than supported by robust, prospective evidence. Second, he pointed to the lack of a comprehensive tool to individualize immunosuppressive therapy, one that integrates biomarkers and clinical features to reduce the risks of over- or under-immunosuppression and improve ongoing monitoring.
He described promising examples already moving the field in that direction, such as cell-free DNA, which has been investigated as a tool that may help reduce the need for some biopsies and viral assays that may help assess the balance of immune suppression. If resources were unlimited, Dr. Potena said his top priority would be developing better, more practical tools for monitoring and tailoring immunosuppression, specifically a cost-effective, scalable approach that combines biomarkers with patient characteristics to guide immunosuppressive therapy in everyday clinical practice. In his view, the field may be progressing toward making that kind of personalization feasible at scale.
The Heart Transplant Field: Defining the Next Frontier
Dr. Potena described several major shifts he has witnessed that are reshaping outcomes in both transplantation and advanced heart failure. In advanced heart failure, he pointed to the growing availability and impact of Left Ventricular Assist Devices (LVADs), which have been associated with improved survival to transplant in many clinical settings. In transplantation, he highlighted progress in organ perfusion and the expansion of Donation after Circulatory Death (DCD) organ procurement, developments that may help broaden the donor pool and enhance organ utilization. He also noted that in broader heart failure care, new therapeutic classes, such as Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors, have demonstrated benefits in clinical studies.
Looking ahead, Dr. Potena shared clear hopes for the next decade. For advanced heart failure, he would like to see an LVAD without an external driveline, a fully implantable system that may reduce infection risk and improves patient comfort. For transplantation, he envisions machine perfusion advancing to the point where organs can be preserved longer and potentially improved or engineered, expanding utilization and improving outcomes. On xenotransplantation, he expressed optimism about scientific feasibility, while also raising a caution: as the field evolves, including potential changes in how organs are sourced and allocated, the industry must address the implications for equity and access.
Conclusion
When asked what mindset matters most for early-career clinicians who want to make a real impact in advanced heart failure and transplantation, Dr. Potena didn’t start with technology, protocols or procedural mastery. He started with people.
He explained that the first skill is empathy and, just as importantly, the ability to talk with patients and truly understand what they’re experiencing. In his view, many patients in this setting aren’t just dealing with illness; they’re coping with a chronic, life-threatening condition, and not everyone is ready to accept what that means. That can show up as discomfort, doubt or a lack of trust in what clinicians are recommending, and it’s often compounded by social insecurity and psychosocial challenges.
For Dr. Potena, that reality changes what it takes to do the work well. Advanced heart failure and transplant care isn’t something you “complete” with a single intervention. As he put it, this is not like performing a procedure where technical success is the endpoint. He contrasted it with placing a coronary stent, something that certainly requires expertise, but not necessarily the same depth of relationship-building. In transplantation, he emphasized that you have to be empathic because you are taking care of someone through the course of their life, not just through a moment in time.
Then he added a second essential trait: curiosity, the drive to keep learning and to think out of the box. In his experience, patients in this field often present with similar overarching stories but highly specific clinical scenarios, and clinicians need the curiosity and flexibility to navigate the details thoughtfully.
The perspectives shared reflect Dr. Potena’s clinical experience and are intended for educational purposes only. They do not constitute medical advice or specific treatment recommendations.